Compare Schwab US Large Cap Growth ETF (SCHG) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs Smith & Nephew plc — how do they compare? Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 5.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and Smith & Nephew plc for 121 Days on average.
| SCHG | SNN | |
|---|---|---|
Market Cap | $65.01B | $11.10B |
Volume | 8,554,399 | 1,051,703 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $37.17 |
52-Week Low | $28.10 | $26.42 |
Typical Hold Time | 50 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $36.74, down 0.35% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low 0.03% expense ratio and its focus on large-cap growth stocks, though concentration in top holdings remains a structural consideration.
The outlook for SCHG remains positive given its growth orientation and cost efficiency, though investors should monitor concentration risks in top holdings. Market leadership in growth sectors and competitive fees support long-term potential, while sensitivity to tech sector volatility presents the primary near-term risk.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
